ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)
A blood test that tracks lymphoma DNA far below what a PET scan can see, so doctors can tell early who is cured and who will relapse.
Phased variant enrichment and detection sequencing (PhasED-seq, Foresight CLARITY) detects lymphoma ctDNA to parts-per-million by tracking multiple mutations on the same DNA fragment. End-of-treatment undetectable ctDNA predicts cure in DLBCL better than PET in several cohorts; ctDNA-guided escalation and de-escalation trials are opening. clonoSEQ tracks the clonal immunoglobulin rearrangement.
How it works
Deep sequencing of plasma cell-free DNA for tumour-specific mutations or the clonal IG rearrangement, with error suppression via phased variants.
- Sensitivity below PET detection
- Serial, non-invasive, interpretable in days
- Not yet a regulatory endpoint in DLBCL
- Requires baseline tumour profile
Latest papers
topQuery for this technology: (TITLE:"ctDNA monitoring in lymphoma" OR ABSTRACT:"ctDNA monitoring in lymphoma" OR TITLE:"PhasED-seq, clonoSEQ" OR ABSTRACT:"PhasED-seq, clonoSEQ") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), not a curated reading list.